|
|
| (24 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | {{pnc}} | | {{pnc}} |
| − | '''[[RSP - Pregnancy, Neonatology]]''' | + | {{ft|D}} |
| | + | ''which risk factors / underlying conditions make covid worse/better/no effect;'' |
| | | | |
| − | '''[[RSP - On RAS drugs]]''' | + | '''[[RSP - identifying risk factors]]''' |
| | | | |
| − | '''[[RSP - Kidney disease]]'''
| |
| − |
| |
| − | '''[[RSP - any transpnatation]]'''
| |
| − |
| |
| − | '''[[RSP - any on biologicals]]'''
| |
| − |
| |
| − | ''' identifying factors '''
| |
| − | *[https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1 OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients.]
| |
| − | {{tp|p=32233642|t=2020. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32232218|t=2020. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis |pdf=|usr=}}
| |
| − | {{tp|p=32304772|t=ä. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China |pdf=|usr=}}
| |
| − | {{tp|p=32118640|t=ä. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease |pdf=|usr=}}
| |
| − | '''Frailty'''
| |
| − | {{tp|p=32268300|t=2020. Biomarkers of biological age as predictors of COVID-19 disease severity |pdf=|usr=}}
| |
| − | {{tp|p=32339960|t=2020. Clinical characteristics of older patients infected with COVID-19: A descriptive study |pdf=|usr=}}
| |
| − | {{tp|p=32331795|t=ä. Afectacion clinica y sintomatoligica en pacientes mayores de 65 anos por COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32269670|t=2020. Canadian Geriatrics Society COVID-19 Recommendations for Older Adults What Do Older Adults Need To Know?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | '''Comorbidity'''
| |
| − | {{tp|p=32267833|t=2020. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis |pdf=|usr=}}
| |
| − |
| |
| − | ''' Diabetes, Obesity, low androgens'''
| |
| − | {{tp|p=32249357|t=ä. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic |pdf=|usr=}}
| |
| − | *[https://www.dailymail.co.uk/sciencetech/article-8312771/Male-coronavirus-patients-low-testosterone-levels-likely-die-COVID-19.html]
| |
| − | {{tp|p=32345580|t=2020. Diabetes and covid-19: a global health challenge |pdf=|usr=}}
| |
| − | {{tp|p=32345579|t=2020. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | '''Heart'''
| |
| − | {{tp|p=32331955|t=ä. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32326691|t=2020. Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction |pdf=|usr=}}
| |
| − | {{tp|p=32277299|t=2020. Perspective: cardiovascular disease and the Covid-19 pandemic |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32335068|t=ä. Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic Shock |pdf=|usr=}}
| |
| − |
| |
| − | '''Kidney, Hemodialysis'''
| |
| − | {{tp|p=32240718|t=ä. COVID-19 in Hemodialysis Patients: A Report of 5 Cases |pdf=|usr=}}
| |
| − | {{tp|p=32276031|t=ä. COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | '''Cancer'''
| |
| − | {{tp|p=32278878|t=ä. French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32345594|t=2020. Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak |pdf=|usr=}}
| |
| − |
| |
| − | '''On immunomodulators: rheumatic, transplant, dermatology, neurology'''
| |
| − | {{tp|p=32264666|t=2020. Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon|pdf=|usr=}}
| |
| − | {{tp|p=32363045|t=ä. Recommended prophylactic and management strategies for severe acute respiratory syndrome coronavirus 2 infection in transplant recipients |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | '''HIV'''
| |
| − | {{tp|p=32266501|t=ä. Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − | '''other pharmacology'''
| |
| − |
| |
| − | *[https://www.boston25news.com/news/health/high-blood-pressure-drugs-cleared-covid/UC5LTCKKKVDETBWKJDZ2P776XY/ ACEI/AT1RA not risky ?]
| |
| − | *[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 dextrometorphan (antitussive compd)]
| |
| − |
| |
| − |
| |
| − | '''Drug abuse'''
| |
| − | {{tp|p=32266501|t=ä. Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − | '''modifiable - tobacco'''
| |
| − | {{tp|p=32303807|t=ä. Electronic cigarette and vaping should be discouraged during the new coronavirus SARS-CoV-2 pandemic |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | '''indoor livin ppl'''
| |
| − | *[https://justthenews.com/politics-policy/coronavirus/doctors-find-hydroxychloroquin-success-rate-91-urge-arizona-maybe-make no sunlight no vitamin d]
| |
| − |
| |
| − | '''Psychiatry'''
| |
| − | {{tp|p=32294689|t=2020. Schizophrenia and COVID-19: risks and recommendations |pdf=|usr=}}
| |
| | ---- | | ---- |
| | + | ''which characteristics has covid in a diseased patient with underlying disorder/state'' |
| | | | |
| − | {{tp|p=32371563|t=2020. Asthma increases risk of severity of COVID-19 |pdf=|usr=}}
| + | '''[[RSP - Pregnancy, Neonatology]]''' |
| − | {{tp|p=32360479|t=ä. 2019 novel coronavirus disease (COVID-19) in hemodialysis patients: a report of two cases |pdf=|usr=}}
| + | |
| − | {{tp|p=32360811|t=ä. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts |pdf=|usr=}}
| + | |
| − | {{tp|p=32334081|t=ä. HEALTH STATUS OF LIVER TRANSPLANTED PATIENTS DURING THE CORONAVIRUS OUTBREAK IN ITALY: A LARGE SINGLE CENTER EXPERIENCE FROM MILAN |pdf=|usr=}}
| + | |
| − | {{tp|p=32276139|t=2020. COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster |pdf=|usr=}}
| + | |
| − | {{tp|p=32276140|t=2020. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients |pdf=|usr=}}
| + | |
| | | | |
| | + | '''[[RSP - Liver disease]]''' |
| | | | |
| | + | '''[[RSP - Diabetes, Obesity]]''' |
| | | | |
| − | {{tp|p=32271368|t=ä. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission |pdf=|usr=}}
| + | '''[[RSP - Kidney disease]]''' |
| − | {{tp|p=32270178|t=ä. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV |pdf=|usr=}}
| + | |
| − | {{tp|p=32353114|t=ä. Throat Wash Testing and COVID-19 Disease: Should We Put Our Money Where Our Mouth Is?|pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32337584|t=ä. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit |pdf=|usr=}}
| + | '''[[RSP - any transplantation]]''' |
| | | | |
| − | {{tp|p=32304745|t=ä. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China |pdf=|usr=}}
| + | '''[[RSP - any on biologicals]]''' |
| − | {{tp|p=32161990|t=ä. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32328736|t=ä. No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity |pdf=|usr=}}
| + | |
| − | {{tp|p=32376643|t=2020. Postpartum exacerbation of antenatal COVID-19 pneumonia in 3 women |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32357998|t=2020. Cardiac considerations in patients with COVID-19 |pdf=|usr=}}
| + | '''[[RSP - On RAS drugs]]''' |
| − | {{tp|p=32332038|t=2020. Asthma and COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32291526|t=2020. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB |pdf=|usr=}}
| + | |
| − | {{tp|p=32350632|t=2020. Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32300516|t=ä. Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times |pdf=|usr=}}
| + | |
| − | {{tp|p=32247213|t=2020. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc) |pdf=|usr=}}
| + | |
| − | {{tp|p=32298981|t=2020. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations |pdf=|usr=}}
| + | |
| − | {{tp|p=32283499|t=2020. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers |pdf=|usr=}}
| + | |
| − | {{tp|p=32334395|t=ä. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia ? A systematic review, meta-analysis, and meta-regression? |pdf=|usr=}}
| + | |
| − | {{tp|p=32228738|t=ä. Mortality Rate of Infection With COVID-19 in Korea From the Perspective of Underlying Disease |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32256706|t=2020. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?|pdf=|usr=}}
| + | |
| − | {{tp|p=32256705|t=2020. Associations between immune-suppressive and stimulating drugs and novel COVID-19?a systematic review of current evidence |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32328575|t=ä. Age, frailty and diabetes ? triple jeopardy for vulnerability to COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32322805|t=ä. SARS-CoV-2 pandemic expanding in sub-Saharan Africa: Considerations for COVID-19 in people living with HIV |pdf=|usr=}}
| + | |
| − | {{tp|p=32372857|t=2020. COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: ?what the bleep do we know?? |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32134381|t=2020. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32324118|t=2020. Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States |pdf=|usr=}}
| + | |
| − | {{tp|p=32305831|t=ä. Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32232395|t=ä. Initial COVID-19 affecting cardiac patients in China |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32344292|t=2020. COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors |pdf=|usr=}}
| + | |
| − | {{tp|p=32328850|t=ä. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening |pdf=|usr=}}
| + | |
| − | {{tp|p=32322046|t=ä. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32296994|t=ä. The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments |pdf=|usr=}}
| + | |
| − | {{tp|p=C7141546|t=ä. Is low sodium intake a risk factor for severe and fatal COVID-19 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32345527|t=ä. Smoking Habit and Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Related Pneumonia: the unsolved paradox behind the evidence |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32217650|t=2020. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32269089|t=2020. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32269088|t=2020. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study |pdf=|usr=}}
| + | |
| − | {{tp|p=32341104|t=2020. Cardiovascular comorbidity and its impact on patients with Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32350104|t=ä. COVID-19 and Nicotine as a Mediator of ACE-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32341101|t=2020. COVID-19 and Smoking Is Nicotine the Hidden Link?|pdf=|usr=}}
| + | |
| − | {{tp|p=32312864|t=ä. Association between ages and clinical characteristics and outcomes of coronavirus disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32279905|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32284245|t=ä. The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is ?Safe Better than Sorry??|pdf=|usr=}}
| + | |
| − | {{tp|p=32317180|t=ä. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32345072|t=2020. The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32222253|t=2020. COVID-19: lessons from the Italian reproductive medical experience |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32323577|t=ä. What the oncologist needs to know about COVID-19 infection in cancer patients |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32357575|t=2020. COVID-19: A Geriatric Emergency |pdf=|usr=}}
| + | |
| − | {{tp|p=32357582|t=2020. Ageing and COVID-19: What is the Role for Elderly People?|pdf=|usr=}}
| + | |
| − | {{tp|p=32274617|t=2020. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes |pdf=|usr=}}
| + | |
| − | {{tp|p=32199996|t=2020. Infection par le SARS-CoV-2 chez les femmes enceintes: etat des connaissances et proposition de prise en charge par CNGOF |pdf=|usr=}}
| + | |
| − | {{tp|p=32244059|t=ä. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes |pdf=|usr=}}
| + | |
| − | {{tp|p=32302703|t=ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment |pdf=|usr=}}
| + | |
| − | {{tp|p=32292696|t=ä. COVID-19 Infection Unmasking Brugada Syndrome |pdf=|usr=}}
| + | |
| − | {{tp|p=32277387|t=ä. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation |pdf=|usr=}}
| + | |
| − | {{tp|p=32325028|t=ä. G6PD deficiency in COVID-19 pandemic: ?a ghost in the ghost? |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32341442|t=ä. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors?lessons from available evidence and insights into COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32342146|t=ä. COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males?|pdf=|usr=}}
| + | |
| − | {{tp|p=32342336|t=ä. Prevention and Control of COVID-19 in Chronic Kidney Disease |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32146921|t=ä. COVID-19 and gender-specific difference: Analysis of public surveillance data in Hong Kong and Shenzhen, China, from January 10 to February 15, 2020 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32336303|t=ä. Risk factors for severe COVID-19 illness in healthcare workers: Too many unknowns |pdf=|usr=}}
| + | |
| − | {{tp|p=32307025|t=ä. Could COVID-19 represent a negative prognostic factor in patients with stroke?|pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32173574|t=2020. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32335339|t=ä. Case Report: One Case of Coronavirus Desease 2019(COVID-19) in Patient Co-nfected by HIV With a Low CD4+ T Cell Count |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32331343|t=2020. Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32355869|t=ä. The Dermatologist?s Perspective: Why is COVID-19 mortality lower in females than males?|pdf=|usr=}}
| + | |
| − | {{tp|p=32222883|t=ä. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32125452|t=ä. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32297089|t=ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32361701|t=2020. COVID-19 Rapid Guideline in Kidney Transplant Recipients |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32333915|t=ä. Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2 |pdf=|usr=}}
| + | |
| − | {{tp|p=C7152876|t=ä. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan |pdf=|usr=}}
| + | |
| − | {{tp|p=32371047|t=ä. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32224277|t=2020. COVID-19 and immunomodulator/immunosuppressant use in dermatology |pdf=|usr=}}
| + | |
| − | {{tp|p=32199889|t=2020. Should biologics for psoriasis be interrupted in the era of COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32283234|t=ä. Biologics for psoriasis during COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32246966|t=ä. COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution |pdf=|usr=}}
| + | |
| − | {{tp|p=C7160444|t=ä. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32330632|t=ä. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment |pdf=|usr=}}
| + | |
| − | {{tp|p=32305444|t=ä. COVID-19 and racial disparities |pdf=|usr=}}
| + | |
| − | {{tp|p=32283235|t=ä. Various forms of skin rash in COVID-19 : a reply |pdf=|usr=}}
| + | |
| − | {{tp|p=32283233|t=ä. Reply to ?COVID-19 can present with a rash and be mistaken for Dengue?: Petechial rash in a patient with COVID-19 infection |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32330545|t=ä. African American COVID-19 Mortality: A Sentinel Event |pdf=|usr=}}
| + | |
| − | {{tp|p=32305401|t=ä. Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System |pdf=|usr=}}
| + | |
| − | {{tp|p=32154911|t=2020. COVID?19 Presents High Risk to Older Persons |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32233753|t=2020. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?|pdf=|usr=}}
| + | |
| − | {{tp|p=32347144|t=2020. Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors |pdf=|usr=}}
| + | |
| − | {{tp|p=32253068|t=2020. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32370269|t=2020. Smoking and SARS-CoV-2 Disease (COVID-19): Dangerous Liaisons or Confusing Relationships?|pdf=|usr=}}
| + | |
| − | {{tp|p=32244852|t=2020. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19) |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32302955|t=2020. Clinical characteristics and risk assessment of newborns born to mothers with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32303756|t=ä. Impact of anti-tnf? antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32222956|t=ä. Prevalence and impact of diabetes among people infected with SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32299654|t=ä. The first case of COVID-19 infection in a 75-day-old infant in Jahrom City, south of Iran |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32300796|t=ä. A geroscience perspective on COVID-19 mortality |pdf=|usr=}}
| + | |
| − | {{tp|p=32279081|t=ä. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study |pdf=|usr=}}
| + | |
| − | {{tp|p=32360995|t=ä. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32278005|t=ä. Non-alcoholic fatty liver diseases in patients with COVID-19: A etrospective study |pdf=|usr=}}
| + | |
| − | {{tp|p=32348791|t=ä. Clinical characteristics of COVID-19 patients with abnormal liver tests |pdf=|usr=}}
| + | |
| − | {{tp|p=32348790|t=ä. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32305291|t=ä. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32240670|t=2020. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up |pdf=|usr=}}
| + | |
| − | {{tp|p=32171866|t=ä. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32335173|t=ä. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review |pdf=|usr=}}
| + | |
| − | {{tp|p=32335169|t=ä. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32305490|t=ä. Risk Factors Associated with Disease Severity and Length of Hospital Stay in COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32305487|t=ä. Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32269087|t=ä. Novel Coronavirus Infection in Newborn Babies Under 28 Days in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32335336|t=2020. SARS-CoV-2: Is it the newest spark in the TORCH?|pdf=|usr=}} ''Covid19 in neonates''
| + | |
| − | | + | |
| − | {{tp|p=32305459|t=2020. Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32198004|t=ä. A Patient with SARS-CoV-2 Infection during Pregnancy in Qingdao, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32147409|t=ä. Are children less susceptible to COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32272142|t=ä. More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32366317|t=2020. Covid-19?The real role of NSAIDs in Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32298645|t=ä. Neonatal COVID-19: little evidence and the need for more information? |pdf=|usr=}}
| + | |
| − | {{tp|p=32318729|t=ä. Fever without a source in a young infant due to SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32306369|t=ä. The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities |pdf=|usr=}}
| + | |
| − | {{tp|p=32244166|t=2020. Why are pregnant women susceptible to COVID-19? An immunological viewpoint |pdf=|usr=}}
| + | |
| − | {{tp|p=32335513|t=2020. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis |pdf=|usr=}}
| + | |
| − | {{ttp|p=32335512|t=2020. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32373791|t=ä. Sex Differences in Mortality from COVID-19 Pandemic: Are Men Vulnerable and Women Protected?|pdf=|usr=}}
| + | |
| − | {{tp|p=32215589|t=2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32215581|t=2020. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn |pdf=|usr=}}
| + | |
| − | {{tp|p=32058570|t=2020. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32352491|t=ä. Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32250385|t=2020. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32320003|t=ä. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area |pdf=|usr=}}
| + | |
| − | {{tp|p=32167524|t=ä. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32302293|t=2020. COVID-19 in older adults: clinical, psychosocial, and public health considerations |pdf=|usr=}
| + | |
| − | | + | |
| − | {{tp|p=32247631|t=2020. Kidney disease is associated with in-hospital death of patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32354637|t=ä. COVID-19 infection in kidney transplant recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32354634|t=ä. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32363253|t=ä. SARS-CoV-2 Infection in Hospitalized Patients with Kidney Disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32292865|t=2020. COVID-19 and the Renin-Angiotensin System |pdf=|usr=}}
| + | |
| − | {{tp|p=32353326|t=2020. Atypical presentation of COVID-19 in young infants |pdf=|usr=}}
| + | |
| − | {{tp|p=32151335|t=2020. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records |pdf=|usr=}}
| + | |
| − | {{tp|p=32151334|t=2020. What are the risks of COVID-19 infection in pregnant women?|pdf=|usr=}}
| + | |
| − | {{tp|p=32035511|t=2020. 2019-nCoV epidemic: what about pregnancies?|pdf=|usr=}}
| + | |
| − | {{tp|p=32278370|t=2020. The gendered dimensions of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32334645|t=2020. Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32359411|t=ä. COVID-19 and obesity?lack of clarity, guidance, and implications for care |pdf=|usr=}}
| + | |
| − | {{tp|p=32151318|t=2020. Managing neonates with respiratory failure due to SARS-CoV-2 ? Authors reply |pdf=|usr=}}
| + | |
| − | {{tp|p=32151320|t=2020. Managing neonates with respiratory failure due to SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32339474|t=ä. Determining risk factors for mortality in liver transplant patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32278366|t=ä. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy |pdf=|usr=}}
| + | |
| − | {{tp|p=32171057|t=2020. Implications of COVID-19 for patients with pre-existing digestive diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32304642|t=ä. COVID-19 in patients with HIV: clinical case series |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32224304|t=2020. COVID-19 infection in children |pdf=|usr=}}
| + | |
| − | {{tp|p=32142639|t=ä. Guidelines for pregnant women with suspected SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32171067|t=2020. Sex difference and smoking predisposition in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32171062|t=2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32332856|t=ä. COVID-19 in persons with haematological cancers |pdf=|usr=}}
| + | |
| − | {{tp|p=32353398|t=ä. Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32344304|t=ä. May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications ?|pdf=|usr=}}
| + | |
| − | {{tp|p=32339776|t=2020. Covid-19, TMPRSS2, and whether android regulation affects pandemic virus gender incidence and age distribution of disease |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32333196|t=2020. Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32271125|t=2020. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management |pdf=|usr=}}
| + | |
| − | {{tp|p=32220612|t=2020. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32220611|t=2020. Commentary: COVID-19 in patients with diabetes |pdf=|usr=}}
| + | |
| − | {{tp|p=32275971|t=ä. COVID-19 in patients with diabetes: risk factors that increase morbidity |pdf=|usr=}}
| + | |
| − | {{tp|p=32360211|t=ä. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32360397|t=ä. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy |pdf=|usr=}}
| + | |
| − | {{tp|p=32353356|t=ä. Obesity: the ?Achilles heel? for COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32333939|t=2020. Importance of metabolic health in the era of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32333938|t=2020. Obesity hypoventilation syndrome and severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320741|t=2020. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32320740|t=ä. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320742|t=ä. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next? |pdf=|usr=}}
| + | |
| − | {{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32218613|t=ä. Coronaviruserkrankung bei Kindern ? erste Daten aus Wuhan |pdf=|usr=}}
| + | |
| − | {{ttp|p=32317808|t=ä. COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31 03 2020) und erste Daten aus Deutschland |pdf=|usr=}}
| + | |
| − | {{tp|p=32339915|t=ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32315980|t=2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?|pdf=|usr=}}
| + | |
| − | {{tp|p=32348641|t=ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York |pdf=|usr=}}
| + | |
| − | {{tp|p=32187458|t=ä. SARS-CoV-2 Infection in Children |pdf=|usr=}}
| + | |
| − | {{tp|p=32163697|t=2020. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32227760|t=ä. Renin?Angiotensin?Aldosterone System Inhibitors in Patients with Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32302077|t=ä. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32237670|t=ä. An Uncomplicated Delivery in a Patient with Covid-19 in the United States |pdf=|usr=}}
| + | |
| − | {{tp|p=32265531|t=ä. COVID-19 and cancer: what we know so far |pdf=|usr=}}
| + | |
| − | {{tp|p=32346090|t=ä. Does asthma make COVID-19 worse?|pdf=|usr=}}
| + | |
| − | {{tp|p=32246101|t=ä. Controversies of renin?angiotensin system inhibition during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32358609|t=ä. The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?|pdf=|usr=}}
| + | |
| − | {{tp|p=32222703|t=ä. COVID-19 Infection in a Patient with End-Stage Kidney Disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32197096|t=ä. COVID-19 in pregnant women ? Authors reply |pdf=|usr=}}
| + | |
| − | {{tp|p=32283004|t=ä. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery |pdf=|usr=}}
| + | |
| − | {{tp|p=32346676|t=ä. Crowdsourcing a crisis response for COVID-19 in oncology |pdf=|usr=}}
| + | |
| − | {{tp|p=32161408|t=2020. Lack of maternal?fetal SARS-CoV-2 transmission |pdf=|usr=}}
| + | |
| − | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}}
| + | |
| − | {{tp|p=32231328|t=ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32327737|t=ä. Obesity and impaired metabolic health in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32203970|t=ä. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade |pdf=|usr=}}
| + | |
| − | {{tp|p=32311696|t=ä. Comment on ?Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade? |pdf=|usr=}}
| + | |
| − | {{tp|p=32371550|t=2020. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |pdf=|usr=}}
| + | |
| − | {{tp|p=32303856|t=ä. Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32270359|t=ä. Acute stroke management pathway during Coronavirus-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32270358|t=ä. No lockdown for neurological diseases during COVID19 pandemic infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32364125|t=ä. Consulta de epilepsia durante la pandemia de Covid-19: papel de la telemedicina y efectos del confinamiento en pacientes epil�pticos |pdf=|usr=}}
| + | |
| − | {{tp|p=32364122|t=ä. Neuroinfecciones en tiempos de COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32333196|t=2020. Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32271125|t=2020. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management |pdf=|usr=}}
| + | |
| − | {{tp|p=32220612|t=2020. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32220611|t=2020. Commentary: COVID-19 in patients with diabetes |pdf=|usr=}}
| + | |
| − | {{tp|p=32275971|t=ä. COVID-19 in patients with diabetes: risk factors that increase morbidity |pdf=|usr=}}
| + | |
| − | {{tp|p=32360211|t=ä. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32360397|t=ä. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy |pdf=|usr=}}
| + | |
| − | {{tp|p=32353356|t=ä. Obesity: the ?Achilles heel? for COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32333939|t=2020. Importance of metabolic health in the era of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32333938|t=2020. Obesity hypoventilation syndrome and severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320741|t=2020. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32320740|t=ä. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320742|t=ä. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next? |pdf=|usr=}}
| + | |
| − | {{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32218613|t=ä. Coronaviruserkrankung bei Kindern ? erste Daten aus Wuhan |pdf=|usr=}}
| + | |
| − | {{ttp|p=32317808|t=ä. COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31 03 2020) und erste Daten aus Deutschland |pdf=|usr=}}
| + | |
| − | {{tp|p=32339915|t=ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32315980|t=2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?|pdf=|usr=}}
| + | |
| − | {{tp|p=32348641|t=ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York |pdf=|usr=}}
| + | |
| − | {{tp|p=32187458|t=ä. SARS-CoV-2 Infection in Children |pdf=|usr=}}
| + | |
| − | {{tp|p=32163697|t=2020. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32227760|t=ä. Renin?Angiotensin?Aldosterone System Inhibitors in Patients with Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32302077|t=ä. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32237670|t=ä. An Uncomplicated Delivery in a Patient with Covid-19 in the United States |pdf=|usr=}}
| + | |
| − | {{tp|p=32265531|t=ä. COVID-19 and cancer: what we know so far |pdf=|usr=}}
| + | |
| − | {{tp|p=32346090|t=ä. Does asthma make COVID-19 worse?|pdf=|usr=}}
| + | |
| − | {{tp|p=32246101|t=ä. Controversies of renin?angiotensin system inhibition during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32358609|t=ä. The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?|pdf=|usr=}}
| + | |
| − | {{tp|p=32222703|t=ä. COVID-19 Infection in a Patient with End-Stage Kidney Disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32197096|t=ä. COVID-19 in pregnant women ? Authors reply |pdf=|usr=}}
| + | |
| − | {{tp|p=32283004|t=ä. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery |pdf=|usr=}}
| + | |
| − | {{tp|p=32346676|t=ä. Crowdsourcing a crisis response for COVID-19 in oncology |pdf=|usr=}}
| + | |
| − | {{tp|p=32161408|t=2020. Lack of maternal?fetal SARS-CoV-2 transmission |pdf=|usr=}}
| + | |
| − | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}}
| + | |
| − | {{tp|p=32231328|t=ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32327737|t=ä. Obesity and impaired metabolic health in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32203970|t=ä. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade |pdf=|usr=}}
| + | |
| − | {{tp|p=32311696|t=ä. Comment on ?Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade? |pdf=|usr=}}
| + | |
| − | {{tp|p=32371550|t=2020. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |pdf=|usr=}}
| + | |
| − | {{tp|p=32303856|t=ä. Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32270359|t=ä. Acute stroke management pathway during Coronavirus-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32270358|t=ä. No lockdown for neurological diseases during COVID19 pandemic infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32364125|t=ä. Consulta de epilepsia durante la pandemia de Covid-19: papel de la telemedicina y efectos del confinamiento en pacientes epil�pticos |pdf=|usr=}}
| + | |
| − | {{tp|p=32364122|t=ä. Neuroinfecciones en tiempos de COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32333196|t=2020. Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32271125|t=2020. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management |pdf=|usr=}}
| + | |
| − | {{tp|p=32220612|t=2020. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32220611|t=2020. Commentary: COVID-19 in patients with diabetes |pdf=|usr=}}
| + | |
| − | {{tp|p=32275971|t=ä. COVID-19 in patients with diabetes: risk factors that increase morbidity |pdf=|usr=}}
| + | |
| − | {{tp|p=32360211|t=ä. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32360397|t=ä. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy |pdf=|usr=}}
| + | |
| − | {{tp|p=32353356|t=ä. Obesity: the ?Achilles heel? for COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32333939|t=2020. Importance of metabolic health in the era of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32333938|t=2020. Obesity hypoventilation syndrome and severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320741|t=2020. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32320740|t=ä. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320742|t=ä. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next? |pdf=|usr=}}
| + | |
| − | {{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32218613|t=ä. Coronaviruserkrankung bei Kindern ? erste Daten aus Wuhan |pdf=|usr=}}
| + | |
| − | {{ttp|p=32317808|t=ä. COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31 03 2020) und erste Daten aus Deutschland |pdf=|usr=}}
| + | |
| − | {{tp|p=32339915|t=ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32315980|t=2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?|pdf=|usr=}}
| + | |
| − | {{tp|p=32348641|t=ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York |pdf=|usr=}}
| + | |
| − | {{tp|p=32187458|t=ä. SARS-CoV-2 Infection in Children |pdf=|usr=}}
| + | |
| − | {{tp|p=32163697|t=2020. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32227760|t=ä. Renin?Angiotensin?Aldosterone System Inhibitors in Patients with Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32302077|t=ä. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32237670|t=ä. An Uncomplicated Delivery in a Patient with Covid-19 in the United States |pdf=|usr=}}
| + | |
| − | {{tp|p=32265531|t=ä. COVID-19 and cancer: what we know so far |pdf=|usr=}}
| + | |
| − | {{tp|p=32346090|t=ä. Does asthma make COVID-19 worse?|pdf=|usr=}}
| + | |
| − | {{tp|p=32246101|t=ä. Controversies of renin?angiotensin system inhibition during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32358609|t=ä. The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?|pdf=|usr=}}
| + | |
| − | {{tp|p=32222703|t=ä. COVID-19 Infection in a Patient with End-Stage Kidney Disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32197096|t=ä. COVID-19 in pregnant women ? Authors reply |pdf=|usr=}}
| + | |
| − | {{tp|p=32283004|t=ä. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery |pdf=|usr=}}
| + | |
| − | {{tp|p=32346676|t=ä. Crowdsourcing a crisis response for COVID-19 in oncology |pdf=|usr=}}
| + | |
| − | {{tp|p=32161408|t=2020. Lack of maternal?fetal SARS-CoV-2 transmission |pdf=|usr=}}
| + | |
| − | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}}
| + | |
| − | {{tp|p=32231328|t=ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32327737|t=ä. Obesity and impaired metabolic health in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32203970|t=ä. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade |pdf=|usr=}}
| + | |
| − | {{tp|p=32311696|t=ä. Comment on ?Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade? |pdf=|usr=}}
| + | |
| − | {{tp|p=32371550|t=2020. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |pdf=|usr=}}
| + | |
| − | {{tp|p=32303856|t=ä. Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32270359|t=ä. Acute stroke management pathway during Coronavirus-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32270358|t=ä. No lockdown for neurological diseases during COVID19 pandemic infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32364125|t=ä. Consulta de epilepsia durante la pandemia de Covid-19: papel de la telemedicina y efectos del confinamiento en pacientes epilepticos |pdf=|usr=}}
| + | |
| − | {{tp|p=32364122|t=ä. Neuroinfecciones en tiempos de COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32372822|t=2020. Why are ethnic minorities worse affected?|pdf=|usr=}}
| + | |
| − | {{tp|p=32372818|t=2020. Men hit harder by covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32372803|t=2020. Children and covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32243722|t=2020. Lessons unfolding from pediatric cases of COVID?19 disease caused by SARS?CoV?2 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32304747|t=2020. Angiotensin receptor blockers and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32360482|t=2020. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?|pdf=|usr=}}
| + | |
| − | {{tp|p=32298273|t=2020. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study |pdf=|usr=}}
| + | |
| − | {{tp|p=32343745|t=2020. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32231171|t=2020. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32329978|t=2020. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32343807|t=ä. The Elderly & COVID-19: Cocooning or Culling: - the choice is ours |pdf=|usr=}}
| + | |
| − | {{tp|p=32219440|t=ä. Are certain drugs associated with enhanced mortality in COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32289171|t=ä. Cardiac drugs and outcome in COVID-19: Reply |pdf=|usr=}}
| + | |
| − | {{tp|p=32289168|t=ä. Cardiac drugs and outcome in COVID - 19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=C7129713|t=ä. Coronavirus: la emergencia geri�trica de 2020 Documento conjunto de la Secci�n de Cardiolog�a Geri�trica de la Sociedad Espa�ola de Cardiolog�a y la Sociedad Espa�ola de Geriatr�a y Gerontolog�a |pdf=|usr=}}
| + | |
| − | {{tp|p=C7151242|t=ä. Controversy regarding ACE inhibitors / ARBs in Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32331829|t=ä. Smoking and coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32362357|t=ä. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum |pdf=|usr=}}
| + | |
| − | {{tp|p=32314010|t=ä. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs |pdf=|usr=}}
| + | |
| − | {{tp|p=32346493|t=ä. Clinical presentations and outcomes of SARS-CoV-2 infected pneumonia in pregnant women and health status of their neonates |pdf=|usr=}}
| + | |
| − | {{tp|p=32335406|t=ä. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32336968|t=2020. COVID-19 outbreak impact in Spain: A role for tobacco smoking?|pdf=|usr=}}
| + | |
| − | {{tp|p=32206052|t=2020. COVID-19 and smoking: A systematic review of the evidence |pdf=|usr=}}
| + | |
| − | {{tp|p=32355638|t=ä. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system |pdf=|usr=}}
| + | |
| − | {{tp|p=32154135|t=2020. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32247017|t=ä. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and COVID-19 infection during pregnancy |pdf=|usr=}}
| + | |
| − | {{tp|p=32314274|t=ä. Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women |pdf=|usr=}}
| + | |
| − | {{tp|p=32050635|t=2020. Potential Maternal and Infant Outcomes from Coronavirus 2019-nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32204755|t=2020. SARS-CoV-2 infection with gastrointestinal symptoms as the first manifestation in a neonate |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32377677|t=ä. COVID-19 in Older People: A Rapid Clinical Review |pdf=|usr=}}
| + | |
| − | {{tp|p=32371056|t=ä. Care of critically ill pregnant patients with coronavirus disease 2019: a case series |pdf=|usr=}}
| + | |
| − | {{tp|p=32228252|t=2020. COVID-19, ACE2, and the cardiovascular consequences |pdf=|usr=}}
| + | |
| − | {{tp|p=32277845|t=2020. Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates |pdf=|usr=}}
| + | |
| − | {{tp|p=32259279|t=2020. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies |pdf=|usr=}}
| + | |
| − | {{tp|p=32356302|t=2020. Antenatal corticosteroid therapy and COVID-19: Pathophysiological considerations |pdf=|usr=}}
| + | |
| − | {{tp|p=32141062|t=2020. Novel corona virus disease (COVID-19) in pregnancy: What clinical recommendations to follow?|pdf=|usr=}}
| + | |
| − | {{tp|p=32212348|t=2020. Why is COVID-19 so mild in children?|pdf=|usr=}}
| + | |
| − | {{tp|p=32339307|t=2020. Additional hypotheses about why COVID-19 is milder in children than adults |pdf=|usr=}}
| + | |
| − | {{tp|p=32279351|t=2020. We urgently need guidelines for managing COVID-19 in children with comorbidities |pdf=|usr=}}
| + | |
| − | {{tp|p=32310898|t=2020. Infection of severe acute respiratory syndrome coronavirus 2 in a patient with acquired immunodeficiency syndrome |pdf=|usr=}}
| + | |
| − | {{tp|p=32186894|t=2020. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32348598|t=2020. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient |pdf=|usr=}}
| + | |
| − | {{tp|p=32359205|t=2020. 2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32358994|t=2020. Asthma and COVID-19: is asthma a risk factor for severe outcomes?|pdf=|usr=}}
| + | |
| − | {{tp|p=32311145|t=2020. SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32243621|t=2020. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient |pdf=|usr=}}
| + | |
| − | {{tp|p=32267016|t=2020. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32380564|t=2020. Caring for Pregnant Patients with COVID-19: Practical Tips Getting from Policy to Practice |pdf=|usr=}}
| + | |
| − | {{tp|p=32217113|t=2020. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy |pdf=|usr=}}
| + | |
| − | {{tp|p=32359227|t=2020. Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32359226|t=2020. COVID-19 and Neonatal Respiratory Care: Current Evidence and Practical Approach |pdf=|usr=}}
| + | |
| − | {{tp|p=32268381|t=2020. Neonatal Resuscitation and Postresuscitation Care of Infants Born to Mothers with Suspected or Confirmed SARS-CoV-2 Infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32305046|t=2020. Severe COVID-19 during Pregnancy and Possible Vertical Transmission |pdf=|usr=}}
| + | |
| − | {{tp|p=32330970|t=2020. Successful Treatment of Preterm Labor in Association with Acute COVID-19 Infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32233067|t=ä. COVID?19 in kidney transplant recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32233057|t=ä. Novel Coronavirus?19 (COVID?19) in the immunocompromised transplant recipient: #Flatteningthecurve |pdf=|usr=}}
| + | |
| − | {{tp|p=32198834|t=ä. Case report of COVID?19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?|pdf=|usr=}}
| + | |
| − | {{tp|p=32181990|t=ä. Successful recovery of COVID?19 pneumonia in a renal transplant recipient with long?term immunosuppression |pdf=|usr=}}
| + | |
| − | {{tp|p=32243698|t=ä. Immunosuppression drug?related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis |pdf=|usr=}}
| + | |
| − | {{tp|p=32329629|t=2020. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32378314|t=2020. Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options |pdf=|usr=}}
| + | |
| − | {{tp|p=32368838|t=2020. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32359210|t=2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report |pdf=|usr=}}
| + | |
| − | {{tp|p=32243690|t=2020. A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32243697|t=2020. COVID-19 in posttransplant patients-report of 2 cases |pdf=|usr=}}
| + | |
| − | {{tp|p=32243673|t=2020. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient |pdf=|usr=}}
| + | |
| − | {{tp|p=32324331|t=2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine |pdf=|usr=}}
| + | |
| − | {{tp|p=32243672|t=2020. SARS Cov-2 infection in a renal-transplanted patient: A case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32351040|t=2020. COVID-19 in kidney transplant recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32337859|t=2020. Two distinct cases with COVID-19 in kidney transplant recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32337790|t=2020. Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics |pdf=|usr=}}
| + | |
| − | {{tp|p=32330356|t=2020. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States |pdf=|usr=}}
| + | |
| − | {{tp|p=32330343|t=2020. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter |pdf=|usr=}}
| + | |
| − | {{tp|p=32319218|t=2020. A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant |pdf=|usr=}}
| + | |
| − | {{tp|p=32315122|t=2020. COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient |pdf=|usr=}}
| + | |
| − | {{tp|p=32301155|t=2020. COVID-19 in solid organ transplant recipients: A single-center case series from Spain |pdf=|usr=}}
| + | |
| − | {{tp|p=32282991|t=2020. Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32282986|t=2020. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32277555|t=2020. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32282977|t=2020. First case of COVID-19 in a kidney transplant recipient treated with belatacept |pdf=|usr=}}
| + | |
| − | {{tp|p=32277591|t=2020. Fatal outcome in a liver transplant recipient with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32339251|t=2020. The importance of hypertension as a risk factor for severe illness and mortality in COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32243894|t=2020. COVID-19 infection in cancer patients: early observations and unanswered questions |pdf=|usr=}}
| + | |
| − | {{tp|p=32224151|t=2020. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32241792|t=2020. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD |pdf=|usr=}}
| + | |
| − | {{tp|p=32354772|t=2020. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept |pdf=|usr=}}
| + | |
| − | {{tp|p=32332075|t=2020. Patients with lupus are not protected from COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32332072|t=2020. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine |pdf=|usr=}}
| + | |
| − | {{tp|p=32295789|t=2020. Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32327426|t=2020. SLE patients are not immune to covid-19: importance of sending the right message across |pdf=|usr=}}
| + | |
| − | {{tp|p=32295787|t=2020. SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment |pdf=|usr=}}
| + | |
| − | {{tp|p=32321720|t=2020. Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) |pdf=|usr=}}
| + | |
| − | {{tp|p=32312768|t=2020. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32245656|t=2020. COVID-19 in patients with cardiovascular diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32180426|t=2020. An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes |pdf=|usr=}}
| + | |
| − | {{tp|p=32255510|t=2020. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement |pdf=|usr=}}
| + | |
| − | {{tp|p=32369656|t=2020. Coronavirus disease 2019 among pregnant Chinese women: case series data on the safety of vaginal birth and breastfeeding |pdf=|usr=}}
| + | |
| − | {{tp|p=32219995|t=2020. Safe delivery for pregnancies affected by COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32339382|t=2020. Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32324956|t=2020. How should we treat pregnant women infected with SARS-CoV-2?|pdf=|usr=}}
| + | |
| − | {{tp|p=32340018|t=2020. Coronavirus Disease 2019 in a Hemodialysis Patient |pdf=|usr=}}
| + | |
| − | {{tp|p=32220865|t=2020. Non-steroidal anti-inflammatory drugs and covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32205306|t=2020. Covid-19: European drugs agency to review safety of ibuprofen |pdf=|usr=}}
| + | |
| − | {{tp|p=32184201|t=2020. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists |pdf=|usr=}}
| + | |
| − | {{tp|p=32253225|t=2020. Covid-19: NICE advises against using NSAIDs for fever in patients with suspected cases |pdf=|usr=}}
| + | |
| − | {{tp|p=32369736|t=ä. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes |pdf=|usr=}}
| + | |
| − | {{tp|p=32241880|t=2020. Drugs and the renin-angiotensin system in covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32291262|t=2020. Covid-19: Black people and other minorities are hardest hit in US |pdf=|usr=}}
| + | |
| − | {{tp|p=32379903|t=2020. Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32369615|t=2020. Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression |pdf=|usr=}}
| + | |
| − | {{tp|p=32369606|t=2020. COVID-19 Infection and Sickle Cell Disease: A UK Centre Experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32314798|t=2020. COVID-19 infection in patients with sickle cell disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32333398|t=2020. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance |pdf=|usr=}}
| + | |
| − | {{tp|p=32312714|t=2020. COVID-19 More Frequent, Severe in Cancer Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32352633|t=2020. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32302248|t=2020. ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32302265|t=2020. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32339025|t=2020. Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32377468|t=ä. First Case of an Infant with COVID-19 in the Middle East |pdf=|usr=}}
| + | |
| − | {{tp|p=32320270|t=2020. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms |pdf=|usr=}}
| + | |
| − | {{tp|p=32282224|t=2020. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations |pdf=|usr=}}
| + | |
| − | {{tp|p=32345646|t=2020. BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte) |pdf=|usr=}}
| + | |
| − | {{tp|p=32286246|t=2020. COVID-19 infections are also affected by human ACE1 D/I polymorphism |pdf=|usr=}}
| + | |
| − | {{tp|p=32112082|t=2020. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load |pdf=|usr=}}
| + | |
| − | {{tp|p=32220930|t=2020. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32342637|t=2020. COVID-19 and obesity |pdf=|usr=}}
| + | |
| − | {{tp|p=32292054|t=2020. SARS-CoV-2 Infection in a 2-Week-Old Male With Neutropenia |pdf=|usr=}}
| + | |
| − | {{tp|p=32255491|t=2020. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320478|t=2020. Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence |pdf=|usr=}}
| + | |
| − | {{tp|p=32237261|t=ä. The COVID?19 outbreak and rheumatologic skin diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32259878|t=ä. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID?19: Will cases of psoriasis increase after COVID?19 pandemic?|pdf=|usr=}}
| + | |
| − | {{tp|p=32375909|t=ä. Impact of Fundamental Diseases on Patients With COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32129518|t=ä. Angiotensin receptor blockers as tentative SARS?CoV?2 therapeutics |pdf=|usr=}}
| + | |
| − | {{tp|p=32233013|t=ä. Diabetes is a risk factor for the progression and prognosis of COVID?19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32374012|t=2020. Mortality rate and gender differences in COVID-19 patients dying in Italy: A comparison with other countries |pdf=|usr=}}
| + | |
| − | {{tp|p=32189428|t=ä. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID?19 in the general population?|pdf=|usr=}}
| + | |
| − | {{tp|p=32376408|t=ä. Clinical Characteristics and Outcomes of COVID-19 Among Patients with Pre-Existing Liver Disease in United States: A Multi-Center Research Network Study |pdf=|usr=}}
| + | |
| − | {{tp|p=32369240|t=2020. Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind |pdf=|usr=}}
| + | |
| − | {{tp|p=32367558|t=2020. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32356577|t=2020. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration |pdf=|usr=}}
| + | |
| − | {{tp|p=32359088|t=2020. RAAS blockers in hypertension posing a higher risk towards the COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32362061|t=2020. (pat.on)Dupilumab and COVID-19: What should we expect?|pdf=|usr=}}
| + | |
| − | {{tp|p=32259611|t=2020. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used) |pdf=|usr=}}
| + | |
| − | {{tp|p=32356926|t=2020. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32304146|t=2020. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32329083|t=2020. (ang.)COVID-19 transmission through host cell directed network of GPCR |pdf=|usr=}}
| + | |
| − | {{tp|p=32234728|t=2020. EMA advice on the use of NSAIDs for Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32295811|t=2020. EMA advice on renin-angiotensin system medicines during covid-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32357072|t=2020. CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA |pdf=|usr=}}
| + | |
| − | {{tp|p=32376075|t=2020. Oligohydramnion in COVID19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32290680|t=2020. Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers |pdf=|usr=}}
| + | |
| − | {{tp|p=32310915|t=2020. ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32354990|t=2020. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study |pdf=|usr=}}
| + | |
| − | {{tp|p=32239590|t=ä. Clinical findings in a patient with haemophilia A affected by COVID?19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32362297|t=ä. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32376422|t=ä. Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern |pdf=|usr=}}
| + | '''[[RSP - On NSAIDs]]''' |
| − | {{tp|p=32380214|t=ä. Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32245909|t=2020. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis |pdf=|usr=}}
| + | |
| − | {{tp|p=32312788|t=2020. Covid-19 infection in Crohn s disease under treatment with adalimumab |pdf=|usr=}}
| + | |
| − | {{tp|p=32307955|t=2020. COVID-19, THE KIDNEY AND HYPERTENSION |pdf=|usr=}}
| + | |
| − | {{tp|p=32220017|t=2020. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient |pdf=|usr=}}
| + | |
| − | {{tp|p=32340044|t=2020. The ACE-2 in COVID-19: Foe or Friend?|pdf=|usr=}}
| + | |
| − | {{tp|p=32208987|t=2020. Renin-angiotensin system (RAS) blockers and the COVID-19 pandemic: at present there is no evidence to abandon RAS blockers |pdf=|usr=}}
| + | |
| − | {{tp|p=32367746|t=2020. ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective |pdf=|usr=}}
| + | |
| − | {{tp|p=32348166|t=2020. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study |pdf=|usr=}}
| + | |
| − | {{tp|p=32324897|t=2020. Management of the first patient with confirmed COVID-19 in pregnancy in India: From guidelines to frontlines |pdf=|usr=}}
| + | |
| − | {{tp|p=32330287|t=2020. A systematic scoping review of COVID-19 during pregnancy and childbirth |pdf=|usr=}}
| + | |
| − | {{tp|p=32270479|t=2020. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32271947|t=2020. Delivery in pregnant women infected with SARS-CoV-2: A fast review |pdf=|usr=}}
| + | |
| − | {{tp|p=32369616|t=2020. Critically ill pregnant patient with COVID-19 and neonatal death within two hours of birth |pdf=|usr=}}
| + | |
| − | {{tp|p=32310015|t=2020. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature |pdf=|usr=}}
| + | |
| − | {{tp|p=32255507|t=2020. COVID-19 and Older Adults: What We Know |pdf=|usr=}}
| + | |
| − | {{tp|p=32301766|t=ä. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32376098|t=ä. A MULTINATIONAL REPORT TO CHARACTERISE SARS-CoV-2 INFECTION IN PEOPLE WITH CYSTIC FIBROSIS |pdf=|usr=}}
| + | |
| − | {{tp|p=32371817|t=2020. Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?|pdf=|usr=}}
| + | |
| − | {{tp|p=32371814|t=2020. Response to four comments on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?? |pdf=|usr=}}
| + | |
| − | {{tp|p=32371812|t=2020. COVID-19, hypertension and angiotensin receptor-blocking drugs |pdf=|usr=}}
| + | |
| − | {{tp|p=32371810|t=2020. Comment on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?? |pdf=|usr=}}
| + | |
| − | {{tp|p=32345701|t=2020. The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32317402|t=2020. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York |pdf=|usr=}}
| + | |
| − | {{tp|p=32312797|t=2020. COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?|pdf=|usr=}}
| + | |
| − | {{tp|p=32253888|t=2020. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32351121|t=2020. Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder |pdf=|usr=}}
| + | |
| − | {{tp|p=32353193|t=2020. Is the type of diabetes treatment relevant to outcome of COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32162476|t=2020. Diabetes and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32379925|t=2020. Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient |pdf=|usr=}}
| + | |
| − | {{tp|p=32379913|t=2020. Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs |pdf=|usr=}}
| + | |
| − | {{tp|p=32358791|t=2020. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor |pdf=|usr=}}
| + | |
| − | {{tp|p=32330323|t=2020. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports |pdf=|usr=}}
| + | |
| − | {{tp|p=32294258|t=2020. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor |pdf=|usr=}}
| + | |
| − | {{tp|p=32195824|t=2020. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?|pdf=|usr=}}
| + | |
| − | {{tp|p=32242993|t=2020. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk |pdf=|usr=}}
| + | |
| − | {{tp|p=32354293|t=2020. Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32222119|t=ä. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia |pdf=|usr=}}
| + | '''[[RSP - Smoking]]''' |
| − | {{tp|p=32220066|t=ä. SARS?CoV?2 and HIV |pdf=|usr=}}
| + | |
| − | {{tp|p=32115733|t=ä. Coronavirus disease (COVID?19) and neonate: What neonatologist need to know |pdf=|usr=}}
| + | |
| − | {{tp|p=32160316|t=ä. Co?infection of SARS?CoV?2 and HIV in a patient in Wuhan city, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32248565|t=ä. A twin challenge to handle: COVID?19 with pregnancy |pdf=|usr=}}
| + | |
| − | {{tp|p=32374416|t=2020. ACE2 and prognosis of COVID-19 Insights from Bartter s and Gitelman s syndromes patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32369211|t=2020. What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?|pdf=|usr=}}
| + | |
| − | {{tp|p=32369203|t=2020. Smoking links to the severity of Covid-19: An update of a meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32221983|t=2020. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32266994|t=2020. Comment on "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19" |pdf=|usr=}}
| + | |
| − | {{tp|p=32266993|t=2020. Reporting of all cardiac medications and their outcome in COVID - 19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32352576|t=2020. COVID-19 in pregnancy: risk of adverse neonatal outcomes |pdf=|usr=}}
| + | |
| − | {{tp|p=32347975|t=2020. HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey |pdf=|usr=}}
| + | |
| − | {{tp|p=32343410|t=2020. COVID-19 in Tuberculosis patients: a report of three cases |pdf=|usr=}}
| + | |
| − | {{tp|p=32330302|t=2020. Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19" |pdf=|usr=}}
| + | |
| − | {{tp|p=32293753|t=2020. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32293709|t=2020. Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better |pdf=|usr=}}
| + | |
| − | {{tp|p=32285949|t=2020. Computed Tomography Imaging of an HIV-infected Patient with Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32374288|t=2020. Newborns at risk of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32243919|t=2020. A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32369097|t=ä. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| + | '''[[RSP - Pulmonary disease]]''' |
| − | {{tp|p=32380044|t=ä. Obesity could shift severe COVID-19 disease to younger ages |pdf=|usr=}}
| + | |
| − | {{tp|p=32376099|t=ä. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32324209|t=ä. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32242890|t=2020. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers |pdf=|usr=}}
| + | |
| − | {{tp|p=32215598|t=ä. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32171074|t=2020. Comorbidities and multi-organ injuries in the treatment of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32251625|t=2020. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32251539|t=2020. COVID-19 and liver disease |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32329563|t=2020. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis |pdf=|usr=}}
| + | '''[[RSP - Cystic fibrosis]]''' |
| − | {{tp|p=32243068|t=2020. Breastfeeding and coronavirus disease-2019: Ad interim indications of the Italian Society of Neonatology endorsed by the Union of European Neonatal & Perinatal Societies |pdf=|usr=}}
| + | |
| − | {{tp|p=32377709|t=2020. Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality |pdf=|usr=}}
| + | |
| − | {{tp|p=32320556|t=ä. Late-Onset Neonatal Sepsis in a Patient with Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32356627|t=ä. Renin?Angiotensin?Aldosterone System Blockers and the Risk of Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32356625|t=ä. Inhibitors of the Renin?Angiotensin?Aldosterone System and Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32356628|t=ä. Renin?Angiotensin?Aldosterone System Inhibitors and Risk of Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32347572|t=2020. Outcome of Parkinson s Disease Patients Affected by COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32242182|t=2020. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019) |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32281287|t=2020. Risk of COVID?19 for patients with obesity |pdf=|usr=}}
| + | '''[[RSP - Cardiovascular disease]]''' |
| − | {{tp|p=32237212|t=ä. COVID 19 and the Patient with Obesity ? The Editors Speak Out |pdf=|usr=}}
| + | |
| − | {{tp|p=32332320|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32250049|t=ä. COVID?19 infection in a paucisymptomatic infant: Raising the index of suspicion in epidemic settings |pdf=|usr=}}
| + | |
| − | {{tp|p=32365269|t=2020. Obesity and severe COVID-19 disease: a strong association |pdf=|usr=}}
| + | |
| − | {{tp|p=32365275|t=2020. Obesity accompanying COVID-19: the role of epicardial fat |pdf=|usr=}}
| + | |
| − | {{tp|p=32352637|t=2020. Association of Obesity with Disease Severity among Patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32339391|t=2020. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32324968|t=2020. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2?|pdf=|usr=}}
| + | |
| − | {{tp|p=32314871|t=2020. Targeting the Adipose Tissue in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32314868|t=2020. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?|pdf=|usr=}}
| + | |
| − | {{tp|p=32314861|t=2020. Obesity is Associated with Severe Forms of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32286926|t=2020. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths?|pdf=|usr=}}
| + | |
| − | {{tp|p=32319118|t=2020. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover |pdf=|usr=}}
| + | |
| − | {{tp|p=32366612|t=2020. Early Neonatal SARS-CoV-2 Infection Manifesting With Hypoxemia Requiring Respiratory Support |pdf=|usr=}}
| + | |
| − | {{tp|p=32345686|t=2020. Vulnerable Youth and the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32317311|t=2020. Mitigating the Impacts of the COVID-19 Pandemic Response on At-Risk Children |pdf=|usr=}}
| + | |
| − | {{tp|p=32339304|t=2020. Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression |pdf=|usr=}}
| + | |
| − | {{tp|p=32234837|t=2020. COVID-19 and non-communicable diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32304114|t=2020. Preterm delivery in pregnant woman with critical COVID-19 pneumonia and vertical transmission |pdf=|usr=}}
| + | |
| − | {{tp|p=32377638|t=2020. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32319449|t=2020. A pregnant woman and the SARS-CoV-2 infection: how are barriers easily crossed?|pdf=|usr=}}
| + | |
| − | {{tp|p=32374541|t=2020. Diabete et infection a COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32348046|t=2020. Rhumatologie et COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32348045|t=2020. Maladies autoimmunes dans le contexte de la pandemie COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32348044|t=2020. L'hematologie au temps du COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32348042|t=2020. Infection a SARS-CoV-2 et transplantation d'organes solides |pdf=|usr=}}
| + | |
| − | {{tp|p=32301198|t=ä. Case report: A kidney transplant patient with mild COVID?19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32160345|t=ä. ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals |pdf=|usr=}}
| + | |
| − | {{tp|p=32302282|t=2020. Sex- and Gender-specific Observations and Implications for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32364677|t=2020. COVID-19 pneumonia in kidney transplant recipients-Where we are?|pdf=|usr=}}
| + | |
| − | {{tp|p=32279418|t=2020. Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32357273|t=2020. A catabolic state in a kidney transplant recipient with COVID-19 |pdf=|usr=}}
| + | |
| − | {{ttp|p=32180292|t=2020. Coronavirus in pregnancy and delivery: rapid review |pdf=|usr=}}
| + | |
| − | {{tp|p=32266753|t=2020. Intrauterine vertical transmission of SARS-CoV-2: what we know so far |pdf=|usr=}}
| + | |
| − | {{tp|p=32349165|t=2020. Should we stop aspirin prophylaxis in pregnant women diagnosed with COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32304612|t=2020. Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32135587|t=2020. 2019 novel coronavirus infection in a three-month-old baby |pdf=|usr=}}
| + | |
| − | {{tp|p=32234132|t=2020. First case of neonate with COVID-19 in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32268709|t=2020. Attach importance to COVID-19 infection on maternal and infant outcomes |pdf=|usr=}}
| + | |
| − | {{tp|p=32145714|t=2020. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province |pdf=|usr=}}
| + | |
| − | {{tp|p=32164092|t=2020. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32340096|t=2020. Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension |pdf=|usr=}}
| + | |
| − | {{tp|p=32283876|t=2020. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32189489|t=2020. ACE2 in the context of 2019-nCoV infection: friend or foe? |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=C7197241|t=2020. ACEI inhibitors and ARBs do not increase severity of COVID-19 |pdf=|usr=}}
| + | '''[[RSP - Cancer solid]]''' |
| − | {{tp|p=C7183935|t=ä. Status of SARS-CoV-2 infection in patients on renal replacement therapy Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)? |pdf=|usr=}}
| + | |
| − | {{tp|p=C7194925|t=2020. ... COVID-19 para el paciente con insuficiencia cardiaca, trasplante cardiaco y asistencia ventricular ... |pdf=|usr=}}
| + | |
| − | {{tp|p=C7158793|t=2020. Neonatal COVID?19: little evidence and the need for more information? |pdf=|usr=}}
| + | |
| − | {{tp|p=C7169649|t=2020. EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=C7149285|t=ä. Coronaviruserkrankung 2019 (COVID-19) und Schwangerschaft: Übersicht und Bericht des ersten deutschen Falls mit COVID-19 bei Gestationsdiabetes |pdf=|usr=}}
| + | |
| − | {{tp|p=C7149289|t=2020. Regulatory agencies issue advice on use of NSAIDs for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=C7187739|t=ä. Potential Impact of SARS-CoV-2 Infection in HIV-positive Patients in South Africa |pdf=|usr=}}
| + | |
| − | {{tp|p=32387327|t=ä. SARS-CoV-2 in pregnancy: symptomatic pregnant women are only the tip of the iceberg |pdf=|usr=}}
| + | |
| − | {{tp|p=32376317|t=ä. Evidence for and against vertical transmission for SARS-CoV-2 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32292902|t=2020. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a�systematic review and meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32430225|t=ä. Disparities in the Population at Risk of Severe Illness From COVID-19 by Race/Ethnicity and Income |pdf=|usr=}}
| + | |
| − | {{tp|p=C7164917|t=ä. COVID 19: SINDROME FEBRIL Y CL�NICA NEUR�LOGICA EN NEONATO |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32387167|t=ä. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019 |pdf=|usr=}}
| + | '''[[RSP - Cancer hematology]]''' |
| − | {{tp|p=32387456|t=ä. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532) |pdf=|usr=}}
| + | |
| − | {{tp|p=32402433|t=ä. Child with liver transplant recovers from COVID-19 infection A case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32376395|t=2020. SARS-CoV-2 infection among patients with systemic autoimmune diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32376969|t=ä. COVID-19 outcomes in patients with hematologic disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32386820|t=ä. Evidence of mother-to-newborn infection with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32381262|t=ä. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission |pdf=|usr=}}
| + | |
| − | {{tp|p=32389618|t=ä. An infant with a mild SARS-CoV-2 infection detected only by anal swabs: a case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32382516|t=2020. Severe COVID-19 infection in pregnancy requiring intubation without preterm delivery: A case report |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32132140|t=2020. Proposal for prevention and control of the 2019 novel coronavirus disease in newborn infants |pdf=|usr=}}
| + | '''[[RSP - Hematology other]]''' |
| − | {{tp|p=32267499|t=ä. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32377468|t=ä. First Case of an Infant with COVID-19 in the Middle East |pdf=|usr=}}
| + | |
| − | {{tp|p=32402515|t=ä. Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32413819|t=2020. Vitamin D concentrations and COVID-19 infection in UK Biobank |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32408118|t=2020. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis |pdf=|usr=}}
| + | '''[[RSP - HIV]]''' |
| − | {{tp|p=32387864|t=2020. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects |pdf=|usr=}}
| + | |
| − | {{tp|p=32388171|t=2020. SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome |pdf=|usr=}}
| + | |
| − | {{tp|p=32291196|t=2020. Is low sodium intake a risk factor for severe and fatal COVID-19 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32402627|t=ä. Re: Novel Coronavirus COVID-19 in late pregnancy: Outcomes of first nine cases in an inner city London hospital |pdf=|usr=}}
| + | |
| − | {{tp|p=32389521|t=2020. COVID-19 infection in patients following hepato-pancreatico-biliary intervention: An early experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32409114|t=ä. Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32336767|t=2020. Erhöhtes Risiko bei COVID-19: Alter, Vorerkrankung, Demenz |pdf=|usr=}}
| + | '''[[Children_with_covid19_disease|RSP - DIS Children]]''' |
| − | {{tp|p=32248854|t=ä. A potential protective role of losartan against coronavirus-induced lung damage |pdf=|usr=}}
| + | |
| − | {{tp|p=32376408|t=ä. Clinical Characteristics and Outcomes of COVID-19 Among Patients with Pre-Existing Liver Disease in United States: A Multi-Center Research Network Study |pdf=|usr=}}
| + | |
| − | {{tp|p=C7128941|t=2020. COVID19 Presents High Risk to Older Persons |pdf=|usr=}}
| + | |
| − | {{tp|p=32376043|t=ä. Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32380288|t=ä. Genetic susceptibility for COVID-19?associated sudden cardiac death in African Americans |pdf=|usr=}}
| + | |
| − | {{tp|p=32448641|t=ä. Bloqueantes del sistema renina-angiotensina e infeccion por COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32389847|t=2020. Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32294485|t=ä. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan |pdf=|usr=}}
| + | |
| − | {{tp|p=32439209|t=ä. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32376098|t=ä. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis |pdf=|usr=}}
| + | |
| − | {{tp|p=32430156|t=ä. COVID-19 in a pediatric heart transplant recipient: Emergence of donor-specific antibodies |pdf=|usr=}}
| + | |
| − | {{tp|p=C7165097|t=2020. COVID-19 pneumonia in a dual heart?kidney recipient |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32414646|t=2020. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome |pdf=|usr=}}
| + | '''[[RSP - DIS Elderly]]''' |
| − | {{tp|p=32371279|t=ä. Therapeutic Strategy for Patients with Coronavirus Disease 2019 During Left Ventricular Assist Device Supports |pdf=|usr=}}
| + | |
| − | {{tp|p=32305569|t=2020. Novel Coronavirus Disease 2019 in a Patient on Durable Left Ventricular Assist Device Support |pdf=|usr=}}
| + | |
| − | {{tp|p=32360010|t=2020. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32268149|t=2020. An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations |pdf=|usr=}}
| + | |
| − | {{tp|p=32408961|t=ä. Clinical course of patients infected with severe acute respiratory syndrome coronavirus 2 soon after thoracoscopic lung surgery |pdf=|usr=}}
| + | |
| − | {{tp|p=32292915|t=ä. Severe COVID-19 With ARDS in a Patient on Durable LVAD Support |pdf=|usr=}}
| + | |
| − | {{tp|p=32380044|t=2020. Obesity could shift severe COVID-19 disease to younger ages |pdf=|usr=}}
| + | |
| − | {{tp|p=C7202821|t=2020. COVID-19: underlying metabolic health in the spotlight |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32388230|t=2020. Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia |pdf=|usr=}}
| + | '''[[RSP - DIS Male]]''' |
| − | {{tp|p=32389426|t=2020. A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: ...|pdf=|usr=}}
| + | |
| − | {{tp|p=32376099|t=2020. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32475616|t=ä. copd w covid.... |pdf=|usr=}}
| + | |
| − | {{tp|p=32360210|t=2020. Letter to the Editor: Fasting plasma glucose associated with mortality rate in T2DM patients with COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32332868|t=ä. Mechanisms by which angiotensin-receptor blockers increase ACE2 levels |pdf=|usr=}}
| + | |
| − | {{tp|p=32387757|t=2020. Is the oncologic patient more susceptible to covid19 but perhaps less likely to undergo severe infection-related complications due to fewer cytokines storm as a consequent of the associated immunodeficiency?|pdf=|usr=}}
| + | |
| − | {{tp|p=32408147|t=2020. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain |pdf=|usr=}}
| + | |
| − | {{tp|p=32408155|t=2020. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |pdf=|usr=}}
| + | |
| − | {{tp|p=32388458|t=2020. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment |pdf=|usr=}}
| + | |
| − | {{tp|p=32388451|t=2020. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach |pdf=|usr=}}
| + | |
| − | {{tp|p=32388461|t=2020. Rethinking high-risk groups in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32456945|t=ä. Supresi�n de angiotensina II en la infecci�n por el virus SARS-CoV-2: una propuesta terap�utica |pdf=|usr=}}
| + | |
| − | {{tp|p=32456944|t=ä. Alta prevalencia de COVID-19 asintom�tico en hemodi�lisis Aprendiendo d�a a d�a el primer mes de pandemia de COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32389518|t=ä. Situaci�n de la infecci�n por SARS-CoV-2 en pacientes en tratamiento renal sustitutivo Informe del Registro COVID-19 de la Sociedad Espa�ola de Nefrolog�a (SEN) |pdf=|usr=}}
| + | |
| − | {{tp|p=32382684|t=2020. The mutual effects of COVID-19 and obesity |pdf=|usr=}}
| + | |
| − | {{tp|p=32389584|t=ä. Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32377638|t=2020. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32421537|t=2020. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| | | | |
| − | {{tp|p=32292226|t=ä. Coronavirus: la emergencia geriatrica de 2020...|pdf=|usr=}}
| + | '''[[RSP - DIS Race]]''' |
| − | {{tp|p=32418728|t=ä. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32382258|t=2020. Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis |pdf=|usr=}}
| + | |
